Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;36:461-465

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conlin, P. R.
Right arrow Articles by Demopoulos, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conlin, P. R.
Right arrow Articles by Demopoulos, L.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Other hypertension

(Hypertension. 2000;36:461.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients

Paul R. Conlin; Thomas J. Moore; Stephen L. Swartz; Eliav Barr; Lisa Gazdick; Charlena Fletcher; Paul DeLucca; Laura Demopoulos

From the Endocrinology-Hypertension Division, Brigham and Women’s Hospital, Medical Service, Brockton/West Roxbury VA Medical Center, and Harvard Medical School, Boston, Mass (P.R.C., T.J.M., S.L.S.), and the Clinical Development Department, US Human Health, Merck and Co, Inc, West Point, Pa (T.J.M., E.B., L.G., C.F., P.D., L.D.).

Correspondence to Paul R. Conlin, MD, Endocrinology-Hypertension Division, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115. E-mail pconlin{at}rics.bwh.harvard.edu

Abstract—NSAIDs are known to attenuate the effects of some antihypertensive medications. It is not known whether the new class of angiotensin II receptor antagonists is similarly affected. We conducted a multicenter study assessing the effect of indomethacin on the antihypertensive effects of losartan and captopril. After 4 weeks of placebo washout, hypertensive patients received 6 weeks of active antihypertensive therapy with either 50 mg losartan once daily (n=111) or 25 mg captopril twice daily for 1 week, which was increased to 50 mg twice daily for 5 weeks (n=105). This was followed by 1 week of concomitant therapy with indomethacin (75 mg daily). The primary outcome measure was the change in mean 24-hour ambulatory diastolic blood pressure after the addition of indomethacin. Both captopril and losartan significantly lowered ambulatory diastolic blood pressure (losartan -5.3 mm Hg, P<0.001; captopril -5.6 mm Hg, P<0.001) after 6 weeks of therapy. Indomethacin significantly attenuated the 24-hour ambulatory diastolic blood pressure for both losartan (2.2 mm Hg, P<0.05) and captopril (2.7 mm Hg, P<0.001) and also attenuated the effect of captopril on trough sitting diastolic blood pressure. Changes in daytime diastolic blood pressure (7:00 AM to 11:00 PM) were similar to the 24-hour response in both groups. Nighttime diastolic blood pressure (11:01 PM to 6:59 AM) was significantly attenuated in captopril-treated patients (2.0 mm Hg, P<0.05), but losartan was unaffected (0.4 mm Hg). Thus, concurrent treatment with indomethacin similarly attenuates the 24-hour antihypertensive response to losartan and captopril.


Key Words: hypertension, essential • indomethacin • losartan • captopril • blood pressure




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
P. A. Sarafidis and G. L. Bakris
Resistant Hypertension An Overview of Evaluation and Treatment.
J. Am. Coll. Cardiol., November 25, 2008; 52(22): 1749 - 1757.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al.
Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
Circulation, June 24, 2008; 117(25): e510 - e526.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al.
Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
Hypertension, June 1, 2008; 51(6): 1403 - 1419.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. B. White, J. Kent, A. Taylor, K. M. Verburg, J. B. Lefkowith, and A. Whelton
Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors
Hypertension, April 1, 2002; 39(4): 929 - 934.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
NSAIDs Attenuate the Effects of Newer Antihypertensives
Journal Watch Cardiology, December 1, 2000; 2000(1201): 2 - 2.
[Full Text]